Table 1 Patient Characteristics
From: Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials
Patient Characteristics | Prospective Data n = 100 (%) | Retrospective Data n = 85 (%) | Total Cohort n = 185 (%) |
|---|---|---|---|
Sex: | |||
Males | 75 (75%) | 68 (80%) | 143 (77%) |
Females | 25 (25%) | 17 (20%) | 42 (23%) |
Median age (years) | 66(32–88) | 68 (45–84) | 68 (32–88) |
Mean age | 66 | 67 | 67 |
Staging: | |||
Stage IIIB (effusion) | 37 (37%) | 29 (34%) | 66 (36%) |
Stage IV | 63 (63%) | 56 (66%) | 119 (64%) |
Histological Subtype: | |||
Large cell carcinoma | 50 (50%) | 28 (33%) | 78 (42%) |
Adenocarcinoma | 36 (36%) | 31 (36%) | 67 (36%) |
Squamous cell carcinoma | 10 (10%) | 13 (15%) | 23 (12%) |
Bronchoalveolar | 2 (2%) | 4 (5%) | 6 (3%) |
Undifferentiated carcinoma | 2 (2%) | 4 (5%) | 6 (3%) |
Mixed | 0 (0%) | 2 (2%) | 2 (1%) |
Not available | 0 (0%) | 3 (3.5%) | 3 (2%) |
Measurable disease | 88 (88%) | 82 (96%) | 170 (92%) |
Evaluable disease | 4 (4%) | 2 (2%) | 6 (3%) |
Non-measurable disease | 8 (8%) | 1 (1%) | 9 (5%) |
ECOG Performance Status: | |||
ECOG 0 | 28 (28%) | 17 (20%) | 45 (24%) |
ECOG 1 | 35 (35%) | 26 (30.5%) | 61 (33%) |
ECOG 2 | 23 (23%) | 15 (18%) | 38 (20.5%) |
ECOG 3 & 4 | 14 (14%) | 20 (23%) | 34 (19%) |
Not available | 0 (0%) | 7 (8%) | 7 (4%) |
Estimated life expectancy: | |||
<12 weeks | 34 (34%) | 20 (23.5%) | 54 (29%) |
>12 weeks | 66 (66%) | 58 (68%) | 124 (67%) |
Not available | 0 (0%) | 7 (8%) | 7 (4%) |
Weight loss > 10% in 6 weeks | 26 (26%) | 26 (30.5%) | 52 (28%) |
Weight loss Not available | 0 (0%) | 10 (12%) | 10 (5%) |
Incapable of giving informed consent | 1 (1%) | 3 (3.5%) | 4 (2%) |